AstraZeneca (LON:AZN) Stock Keeps “Buy” Rating at Berenberg Bank

Berenberg Bank reaffirmed their buy rating on shares of AstraZeneca (LON:AZN) in a research report report published on Wednesday morning,Digital Look reports. They currently have a £175 price objective on the biopharmaceutical company’s stock.

Other equities research analysts have also issued reports about the company. Royal Bank Of Canada reiterated an “outperform” rating and set a £145 price objective on shares of AstraZeneca in a research note on Tuesday, September 8th. Citigroup lifted their price target on AstraZeneca from £175 to £178 and gave the stock a “buy” rating in a research note on Tuesday, July 28th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a £117 price target on shares of AstraZeneca in a research report on Tuesday, September 29th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a £175 price objective on shares of AstraZeneca in a research note on Wednesday, September 9th. Six analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of £153.57.

AstraZeneca Stock Up 1.9%

AZN opened at £121.80 on Wednesday. The company has a market cap of £188.90 billion, a PE ratio of 18.23, a price-to-earnings-growth ratio of 0.86 and a beta of 0.20. AstraZeneca has a twelve month low of GBX 119.20 and a twelve month high of £157.32. The company has a 50-day moving average price of £120.74 and a 200 day moving average price of £132.20. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 64.10.

Insider Activity at AstraZeneca

In other news, insider Michel Demare acquired 2,500 shares of AstraZeneca stock in a transaction dated Monday, September 14th. The shares were acquired at an average cost of £121.21 per share, for a total transaction of £303,025. Corporate insiders own 0.15% of the company’s stock.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.